Resource Summary Report

Generated by ASWG on Aug 14, 2026

TRA-1-60 Antibody, anti-human, Vio® 488, REAfinity™

RRID:AB_2654228
Type: Antibody

Proper Citation

Miltenyi Biotec Cat# 130-106-872, RRID:AB_2654228

Antibody Information

URL: http://antibodyregistry.org/AB_2654228

Proper Citation: Miltenyi Biotec Cat# 130-106-872, RRID:AB_2654228

Target Antigen: TRA-1-60

Host Organism: human

Clonality: monoclonal

Comments: Applications: MACS Flow Cytometry
Antigen Distribution: ES and iPS cells

Antibody Name: TRA-1-60 Antibody, anti-human, Vio® 488, REAfinity™

Description: This monoclonal targets TRA-1-60

Target Organism: human

Clone ID: clone REA157

Antibody ID: AB_2654228

Vendor: Miltenyi Biotec

Catalog Number: 130-106-872

Record Creation Time: 20250819T225837+0000

Record Last Update: 20250820T035437+0000

Ratings and Alerts

No rating or validation information has been found for TRA-1-60 Antibody, anti-human, Vio® 488, REAfinity™.

No alerts have been found for TRA-1-60 Antibody, anti-human, Vio® 488, REAfinity™.

Data and Source Information

Source: Antibody Registry

Usage and Citation Metrics

We found 28 mentions in open access literature.

Listed below are recent publications. The full list is available at ASWG .

Luo Y, et al. (2026) CRISPR/Cas9 engineered and whole-genome characterized KIT D816V-mutant human iPSC lines. Stem cell research, 93, 103975.

Lewis K, et al. (2025) Generation of ten human induced pluripotent stem cell lines (hiPSCs) from patients with and without Chemotherapy-Induced Peripheral Neuropathy (CIPN) and Post Chemotherapy Cognitive Impairment (PCCI). Stem cell research, 84, 103674.

Finke M, et al. (2025) Generation of four human induced pluripotent stem cell lines from functionally distinct T cell lineages with defined or undefined T cell receptor specificity. Stem cell research, 88, 103813.

Stadager J, et al. (2025) CRISPR GENome and epigenome engineering improves loss-of-function genetic-screening approaches. Cell reports methods, 5(6), 101078.

Fernandez Vallone V, et al. (2025) Generation of 5 hiPSC lines from pediatric patients with Heritable pulmonary arterial hypertension (HPAH) caused by heterozygous mutations in the TBX4 gene. Stem cell research, 90, 103886.

Haschke AM, et al. (2025) Reprogramming of two induced pluripotent stem cell clones from a patient with a novel MT-ATP6/8 mutation (m.8570 T > C). Stem cell research, 86, 103732.

Härting N, et al. (2025) Generation of hiPSC lines with fusion tagged thyroid hormone receptor ? isoforms to study isoform-specific actions of TR?1 and TR?2. Stem cell research, 86, 103720.

Ludwik KA, et al. (2025) Generation of two human induced pluripotent stem cell lines from Allan-Herndon-Dudley syndrome (AHDS) patients with SLC16A2:G401R or SLC16A2: H192R mutation. Stem cell research, 86, 103725.

Ludwik KA, et al. (2025) Correction of the Allan-Herndon-Dudley syndrome-causing SLC16A2 mutation G401R in a patient derived hiPSC line. Stem cell research, 85, 103698.

Ludwik KA, et al. (2025) Generation of human induced pluripotent stem cell line from an obesity patient with POMC deficiency due to POMC:W84X mutation. Stem cell research, 88, 103814.

Ludwik KA, et al. (2025) Generation of an isogenic iPSC line via CRISPR correction of the POMC:W84X mutation for monogenic obesity modeling. Stem cell research, 87, 103786.

Ludwik KA, et al. (2024) Generation of THRB-GS(E125G_G126S) and THRB-KO human iPSC lines to study noncanonical thyroid hormone signalling. Stem cell research, 74, 103275.

Schreiber MK, et al. (2024) Generation of a fluorescent oligodendrocyte reporter line in human induced pluripotent stem cells. Stem cell research, 75, 103295.

Hernández D, et al. (2024) Generation of a gene-corrected human isogenic iPSC line from an Alzheimer's disease iPSC line carrying the PSEN1 H163R mutation. Stem cell research, 79, 103495.

Haschke AM, et al. (2024) Characterization of two iPSC lines from patients with maternally inherited leigh (MILS) and neuropathy, ataxia, and retinitis pigmentosa (NARP) syndrome carrying the MT-ATP6 m.8993 T>G mutation at different degrees of heteroplasmy. Stem cell research, 81, 103547.

Aline Schmoll K, et al. (2024) Genome engineering of a neuronal specific, optogenetic, induced pluripotent stem cell line. Stem cell research, 75, 103317.

Ludwik KA, et al. (2024) Generation of two human induced pluripotent stem cell lines with BAX and BAK1 double knock-out using CRISPR/Cas9. Stem cell research, 76, 103377.

Schreiber MK, et al. (2024) Generation of Pelizaeus-Merzbacher disease (PMD) mutant (PLP1-C33Y) in induced pluripotent stem cell (iPSC) by CRISPR/Cas9 genome editing. Stem cell research, 74, 103276.

Miller DC, et al. (2023) Generation of an induced pluripotent stem cell line from a Huntington's disease patient with a long HTT-PolyQ sequence. Stem cell research, 68, 103056.

Henke MT, et al. (2023) Generation of two mother-child pairs of iPSCs from maternally inherited Leigh syndrome patients with m.8993 T > G and m.9176 T > G MT-ATP6 mutations. Stem cell research, 67, 103030.